Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

TAK-637. Takeda.

J B Furness1

  • 1Department of Anatomy and Cell Biology, University of Melbourne, Victoria, Australia. j.furness@unimelb.edu.au

Current Opinion in Investigational Drugs (London, England : 2000)
|March 14, 2002
PubMed
Summary
This summary is machine-generated.

TAK-637, an oral NK1 antagonist, is being developed for urinary incontinence, depression, and irritable bowel syndrome. Clinical trials were ongoing in Europe, Japan, and the US as of October 2000.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Heat stress of gilts around farrowing causes oxygen insufficiency in the umbilical cord and reduces piglet survival.

Animal : an international journal of animal bioscience·2022
Same author

The first brain: Species comparisons and evolutionary implications for the enteric and central nervous systems.

Neurogastroenterology and motility·2017
Same author

Heterogeneity of enterochromaffin cells within the gastrointestinal tract.

Neurogastroenterology and motility·2017
Same author

Restoration of intestinal function in an MPTP model of Parkinson's Disease.

Scientific reports·2016
Same author

Site and mechanism of the colokinetic action of the ghrelin receptor agonist, HM01.

Neurogastroenterology and motility·2015
Same author

COMPARATIVE GUT PHYSIOLOGY SYMPOSIUM: Comparative physiology of digestion.

Journal of animal science·2015

Area of Science:

  • Pharmacology
  • Neuroscience
  • Gastroenterology

Background:

  • Abbott and Takeda are developing TAK-637, an orally active NK1 antagonist.
  • The drug is being investigated for multiple conditions including urinary incontinence, depression, and irritable bowel syndrome (IBS).

Purpose of the Study:

  • To evaluate the efficacy and safety of TAK-637 in treating urinary incontinence, depression, and IBS.
  • To determine the optimal dosage and administration of TAK-637.

Main Methods:

  • Phase I and Phase II clinical trials were conducted in Europe, Japan, and the US.
  • Participants received TAK-637 for the treatment of target conditions.

Main Results:

  • By November 1999, Phase I trials were completed in Japan and the US, and Phase II trials were underway in Europe for urinary incontinence.

Related Experiment Videos

  • By October 2000, Phase II trials were initiated in the US for urinary incontinence, depression, and IBS.
  • These trials were scheduled to conclude in 2002.

    • Conclusions:

    • TAK-637 demonstrated potential as a therapeutic agent for urinary incontinence, depression, and IBS.
    • Further clinical development and analysis are required to confirm its efficacy and safety profile.